Efthimios Dardiotis1, Maria Sokratous1, Zisis Tsouris1, Vasileios Siokas1, Alexios-Fotios A Mentis2,3, Athina-Maria Aloizou1, Amalia Michalopoulou1, Dimitrios P Bogdanos4,5, Georgia Xiromerisiou1, Georgia Deretzi6, Jannis Kountouras7, Georgios M Hadjigeorgiou1,8. 1. Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece. 2. Department of Microbiology, University Hospital of Larissa, University of Thessaly, Larissa, Greece. 3. Public Health Laboratories, Hellenic Pasteur Institute, Athens, Greece. 4. Department of Rheumatology and Clinical Immunology, University General Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece. 5. Cellular Immunotherapy & Molecular Immunodiagnostics, Biomedical Section, Centre for Research and Technology-Hellas (CERTH)-Institute for Research and Technology-Thessaly (IRETETH), Larissa, Greece. 6. Department of Neurology, Papageorgiou General Hospital, Thessaloniki, Greece. 7. Department of Medicine, Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece. 8. Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus.
Abstract
BACKGROUND: Helicobacter pylori (H pylori) is a Gram-negative bacterium, considered to trigger autoimmune gastrointestinal disorders. This pathogen has also been linked to the autoimmune sequelae in extra-gastrointestinal diseases and peripheral neuropathies. Guillain-Barré syndrome (GBS) is a serious autoimmune demyelinating disorder of peripheral nerves, usually with a post-infectious onset. About 30% of cases of GBS attributed to by Campylobacter jejuni, so, H pylori, could be also involved. Growing evidence suggests the likely involvement of H pylori infection in the development of GBS. The aim of the current study was to therefore estimate the prevalence of H pylori antibodies in GBS. METHODS: A search of the literature was performed, using the PUBMED database, until December 2018. Data were extracted from six case-control studies, and a stratification analysis was conducted according to cerebrospinal fluid (CSF) or serum detection material. RESULTS: Among 29 records found, 6 studies met in the inclusion criteria for the meta-analysis. In the CSF subgroup, 105 participants were involved (40 GBS patients and 65 controls), while the serum subgroup included 325 participants (152 GBS and 173 controls). Data were combined using a fixed-effects model. Anti-H pylori IgG were significantly more prevalent in GBS patients compared to controls, in both CSF (95% CI: 9.66-186.56, OR: 42.45, Pz < .00001) and serum (95% CI: 1.30-4.11, OR: 2.31, Pz: .004) subgroups. CONCLUSION: The present meta-analysis showed a strong association between GBS and the presence of H pylori antibodies, especially in CSF, thereby suggesting a role of H pylori infection in the pathophysiology of GBS.
BACKGROUND:Helicobacter pylori (H pylori) is a Gram-negative bacterium, considered to trigger autoimmune gastrointestinal disorders. This pathogen has also been linked to the autoimmune sequelae in extra-gastrointestinal diseases and peripheral neuropathies. Guillain-Barré syndrome (GBS) is a serious autoimmune demyelinating disorder of peripheral nerves, usually with a post-infectious onset. About 30% of cases of GBS attributed to by Campylobacter jejuni, so, H pylori, could be also involved. Growing evidence suggests the likely involvement of H pylori infection in the development of GBS. The aim of the current study was to therefore estimate the prevalence of H pylori antibodies in GBS. METHODS: A search of the literature was performed, using the PUBMED database, until December 2018. Data were extracted from six case-control studies, and a stratification analysis was conducted according to cerebrospinal fluid (CSF) or serum detection material. RESULTS: Among 29 records found, 6 studies met in the inclusion criteria for the meta-analysis. In the CSF subgroup, 105 participants were involved (40 GBS patients and 65 controls), while the serum subgroup included 325 participants (152 GBS and 173 controls). Data were combined using a fixed-effects model. Anti-H pylori IgG were significantly more prevalent in GBS patients compared to controls, in both CSF (95% CI: 9.66-186.56, OR: 42.45, Pz < .00001) and serum (95% CI: 1.30-4.11, OR: 2.31, Pz: .004) subgroups. CONCLUSION: The present meta-analysis showed a strong association between GBS and the presence of H pylori antibodies, especially in CSF, thereby suggesting a role of H pylori infection in the pathophysiology of GBS.
Authors: K L Hutchins; J H Jansen; A D Comer; R V Scheer; G S Zahn; A E Capps; L M Weaver; N A Koontz Journal: AJNR Am J Neuroradiol Date: 2020-06-25 Impact factor: 3.825
Authors: Maria Luísa Cordeiro Santos; Breno Bittencourt de Brito; Filipe Antônio França da Silva; Mariana Miranda Sampaio; Hanna Santos Marques; Natália Oliveira E Silva; Dulciene Maria de Magalhães Queiroz; Fabrício Freire de Melo Journal: World J Gastroenterol Date: 2020-07-28 Impact factor: 5.742